Persons with Alzheimer's disease (AD) present with changes in mood, sleep, and arousal that may precede the clinical manifestation of cognitive decline. These early symptoms can be driven by changes in the serotonergic (5-HT) nuclei of the brainstem, particularly the dorsal raphe nucleus (DRN). It is unclear why all 5-HT neurons do not simultaneously develop AD pathology that progresses at the same rate.
Objective
We sought to identify any underlying genetic components associated with susceptibility or resistance of 5-HT neurons to AD pathology.
Methods
The Visium Spatial Gene Expression platform was used to identify transcriptomic changes across the DRN in a preclinical model of early AD, human tau-overexpressing mice (htau mice). We further used RNAscope and immunohistochemical assessment to validate findings of primary interest.
Results
We find that the DRN of htau mice differentially expresses AD-related genes, including those related to kinase binding, ion channel activity, ligand-receptor interactions, and regulation of serine/threonine kinases. We further find that computational sub-clustering of the DRN is consistent with previous circuitry-driven characterizations, allowing for spatial bounding of distinct subregions within the DRN. Of these, we find the dorsolateral DRN is preferentially impacted by 5-HT neuron loss and development of tau pathology, which coincides with increased expression of the long noncoding RNA Map2k3os.
Conclusions
Map2k3os may serve regulatory roles relevant for tau phosphorylation and warrants further investigation to characterize its interactions. Overall, this report demonstrates the power of large-scale spatial transcriptomics technologies, while underscoring the need for convergent-data validation to overcome their limitations.
RajanKBWeuveJBarnesLL, et al.Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020–2060). Alzheimers Dement2021; 17: 1966–1975.
3.
RabarisonKMBouldinEDBishCL, et al.The economic value of informal caregiving for persons with dementia: results from 38 states, the district of Columbia, and Puerto Rico, 2015 and 2016 BRFSS. Am J Public Health2018; 108: 1370–1377.
4.
IqbalKLiuFGongC-X, et al.Tau in Alzheimer disease and related tauopathies. Curr Alzheimers Res2010; 7: 656–664.
5.
Grundke-IqbalIIqbalK. Tau pathology generated by overexpression of tau. Am J Pathol1999; 155: 1781–1785.
6.
HigginsLSRodemsJMCatalanoR, et al.Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751. Proc Natl Acad Sci U S A1995; 92: 4402–4406.
7.
NeveRLBoyceFMMcPhieDL, et al.Transgenic mice expressing APP-C100 in the brain. Neurobiol Aging1996; 17: 191–203.
8.
Sturchler-PierratCAbramowskiDDukeM, et al.Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A1997; 94: 13287–13292.
9.
MoecharsDDewachterILorentK, et al.Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem1999; 274: 6483–6492.
10.
OddoSVasilevkoVCaccamoA, et al.Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem2006; 281: 39413–39423.
11.
LeeVMYBalinBJOtvosL, et al.A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science1991; 251: 675–678.
12.
HasegawaMMorishima-KawashimaMTakioK, et al.Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain. J Biol Chem1992; 267: 17047–17054.
13.
VincentIRosadoMKimE, et al.Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of τ. J Neurochem1994; 62: 715–723.
14.
DrewesGTrinczekBIllenbergerS, et al.Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark): a novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem1995; 270: 7679–7688.
15.
PaudelHK. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J Biol Chem1997; 272: 1777–1785.
16.
IllenbergerSZheng-FischhöferQPreussU, et al.The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol Biol Cell1998; 9: 1495–1512.
17.
WoodsYLCohenPBeckerW, et al.The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J2001; 355(Pt 3): 609–615.
18.
ChoJHJohnsonGVW. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem2004; 88: 349–358.
19.
LeeGThangavelRSharmaVM, et al.Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci2004; 24: 2304–2312.
20.
LiGYinHKuretJ. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem2004; 279: 15938–15945.
21.
SatoSCernyRLBuescherJL, et al.Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem2006; 98: 1573–1584.
22.
YangYCLinCHLeeEHY. Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau. Mol Cell Biol2006; 26: 8357–8370.
23.
YoshidaK. Role for DYRK family kinases on regulation of apoptosis. Biochem Pharmacol2008; 76: 1389–1394.
24.
AlonsoADCGrundke-IqbalIIqbalK. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med1996; 2: 783–787.
25.
AlonsoADCGrundke-IqbalIBarraHS, et al.Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A1997; 94: 298–303.
26.
BiernatJGustkeNDrewesG, et al.Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron1993; 11: 153–163.
27.
BarghornSMandelkowE. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochem2002; 41: 14885–14896.
28.
ChenCPLHEastwoodSLHopeT, et al.Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer’s disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol2000; 26: 347–355.
29.
RübUDel TrediciKSchultzC, et al.The evolution of Alzheimer’s disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol2000; 26: 553–567.
30.
OikonomouGAltermattMZhangRW, et al.The serotonergic raphe promote sleep in zebrafish and mice. Neuron2019; 103: 686–701. e8.
31.
Jeltsch-DavidHKoenigJCasselJC. Modulation of cholinergic functions by serotonin and possible implications in memory: general data and focus on 5-HT1A receptors of the medial septum. Behav Brain Res2008; 195: 86–97.
32.
SumiyoshiTKunugiHNakagomeK. Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Front Neurosci2014; 8: 102018.
33.
VennerABroadhurstRYSohnLT, et al.Selective activation of serotoninergic dorsal raphe neurons facilitates sleep through anxiolysis. Sleep2020; 43: zsz231.
34.
SmithHRLeiboldNKRappoportDA, et al.Dorsal raphe serotonin neurons mediate CO2-induced arousal from sleep. J Neurosci2018; 38: 1915–1925.
35.
MurrayNMBuchananGFRichersonGB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep2015; 38: 1985–1993.
36.
MeltzerCCSmithGDekoskyST, et al.Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology1998; 18: 407–430.
37.
HendricksenMThomasAJFerrierM, et al.Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer’s disease with and without depression. Am J Psychiatry2004; 161: 1096–1102.
38.
ModregoPJ. Depression in Alzheimer’s disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis2010; 21: 1077–1087.
39.
MichelsenKAPrickaertsJSteinbuschHWM. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res2008; 172: 233–264.
40.
PiersonSRKollingLJJamesTD, et al.Serotonergic dysfunction may mediate the relationship between alcohol consumption and Alzheimer’s disease. Pharmacol Res2024; 203: 107171.
41.
IshimuraKTakeuchiYFujiwaraK, et al.Quantitative analysis of the distribution of serotonin-immunoreactive cell bodies in the mouse brain. Neurosci Lett1988; 91: 265–270.
42.
RenJFriedmannDXiongJ, et al.Anatomically defined and functionally distinct dorsal raphe serotonin sub-systems. Cell2018; 175: 472–487. e20.
43.
HuangKWOchandarenaNEPhilsonAC, et al.Molecular and anatomical organization of the dorsal raphe nucleus. Elife2019; 8: e46464.
44.
KhanKMBalasubramanianNGaudencioG, et al.Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer’s disease. Acta Neuropathol Commun2023; 11: 57.
45.
PolydoroMAckerCMDuffK, et al.Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci2009; 29: 10741–10749.
46.
AndorferCKressYEspinozaM, et al.Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem2003; 86: 582–590.
47.
Dengler-CrishCMSmithMAWilsonGN. Early evidence of low bone density and decreased serotonergic synthesis in the dorsal raphe of a tauopathy model of Alzheimer’s disease. J Alzheimers Dis2017; 55: 1605.
48.
HaoYStuartTKowalskiMH, et al.Dictionary learning for integrative, multimodal, and massively scalable single-cell analysis. Nat Biotechnol2024; 42: 293.
49.
LoveMIHuberWAndersS. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol2014; 15: 550.
LubbeSFilzmoserPTemplM. Comparison of zero replacement strategies for compositional data with large numbers of zeros. Chemometr Intell Lab Syst2021; 210: 104248.
53.
Martín-FernándezJABarceló-VidalCPawlowsky-GlahnV. Dealing with zeros and missing values in compositional data sets using nonparametric imputation. Math Geol2003; 35: 253–278.
54.
BirminghamASelforsLMForsterT, et al.Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods2009; 6: 569–575.
55.
ZhangXD. A method for effectively comparing gene effects in multiple conditions in RNAi and expression-profiling research. Pharmacogenomics2009; 10: 345–358.
56.
CohenRKatzirL. The generalized maximum coverage problem. Inf Process Lett2008; 108: 15–22.
57.
CormenTHLeisersonCERivestRL. Introduction to algorithms, second edition. Computer (Long Beach Calif)2001; 7: 1184.
58.
LueckenMDTheisFJ. Current best practices in single-cell RNA-seq analysis: a tutorial. Mol Syst Biol2019; 15: 8746.
59.
DraghiciSKhatriPTarcaAL, et al.A systems biology approach for pathway level analysis. Genome Res2007; 17: 1537.
60.
DonatoMXuZTomoiagaA, et al.Analysis and correction of crosstalk effects in pathway analysis. Genome Res2013; 23: 1885.
61.
AhsanSDrăghiciS. Identifying significantly impacted pathways and putative mechanisms with iPathwayGuide. Curr Protoc Bioinformatics2017; 57: 7.15.1–7.15.30.
62.
SecciMEReedTQuinlanV, et al.Quantitative analysis of gene expression in RNAscope-processed brain tissue. Bio Protoc2023; 13: 4580.
63.
SalamehSNouelDFloresC, et al.An optimized immunohistochemistry protocol for detecting the guidance cue netrin-1 in neural tissue. MethodsX2017; 5: 1–7.
64.
CurcioCAKemperT. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol1984; 43: 359–368.
65.
GrinbergLTRübUFerrettiREL, et al.The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?Neuropathol Appl Neurobiol2009; 35: 406–416.
66.
WangJZGrundke-IqbalIIqbalK. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci2007; 25: 59–68.
67.
AlonsoADCZaidiTGrundke-IqbalI, et al.Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A1994; 91: 5562–5566.
68.
RenJIsakovaAFriedmannD, et al.Single-cell transcriptomes and whole-brain projections of serotonin neurons in the mouse dorsal and median raphe nuclei. Elife2019; 8: e49424.
69.
HuentelmanMJPirasISSiniardAL, et al.Associations of MAP2K3 gene variants with superior memory in SuperAgers. Front Aging Neurosci2018; 10: 155.
70.
BianLTraurigMHansonRL, et al.MAP2K3 Is associated with body mass index in American Indians and caucasians and may mediate hypothalamic inflammation. Hum Mol Genet2013; 22: 4438.
71.
AlafuzoffIArzbergerTAl-SarrajS, et al.Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe consortium. Brain Pathol2008; 18: 484.
72.
NeddensJTemmelMFlunkertS, et al.Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun2018; 6: 52.
73.
SchaefferHJWeberMJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol1999; 19: 2435.
74.
RouxPPBlenisJ. ERK And p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev2004; 68: 320.
75.
DrewesGLichtenberg-KraagBDoringF, et al.Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J1992; 1: 2131–2138.
76.
QiHPrabakaranSCantrelleFX, et al.Characterization of neuronal tau protein as a target of extracellular signal-regulated kinase. J Biol Chem2016; 291: 7742–7753.
77.
LiuFIqbalKGrundke-IqbalI, et al.Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer’s disease. J Biol Chem2005; 280: 1790–1796.
78.
CrippsDThomasSNJengY, et al.Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem2006; 281: 10825–10838.
79.
TimmTMarxAPanneerselvamS, et al.Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of tau protein. BMC Neurosci2008; 9(Suppl 2): S9.
80.
DrewesGEbnethAPreussU, et al.MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell1997; 89: 297–308.
81.
LundHGustafssonESvenssonA, et al.MARK4 And MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies. Acta Neuropathol Commun2014; 2: 22.
82.
GuGJLundHWuD, et al.Role of individual MARK isoforms in phosphorylation of tau at ser 262 in Alzheimer’s disease. Neuromolecular Med2013; 15: 458–469.
83.
AndoKMaruko-OtakeAOhtakeY, et al.Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and Aβ42-induced tau toxicity. PLoS Genet2016; 12: e1005917.
84.
JiZSongRRegevA, et al.Many lncRNAs, 5’UTRs, and pseudogenes are translated and some are likely to express functional proteins. Elife2015; 4: e08890.
85.
StatelloLGuoCJChenLL, et al.Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol2020; 22: 96–118.
86.
UematsuMNakamuraAEbashiM, et al.Brainstem tau pathology in Alzheimer’s disease is characterized by increase of three repeat tau and independent of amyloid β. Acta Neuropathol Commun2018; 6: 1.
87.
PatthyÁMuraiJHanicsJ, et al.Neuropathology of the brainstem to mechanistically understand and to treat Alzheimer’s disease. J Clin Med2021; 10: 1555.
88.
SimicGStanicGMladinovM, et al.Does Alzheimer’s disease begin in the brainstem?Neuropathol Appl Neurobiol2009; 35: 532–554.
89.
SawchenkoPESwansonLWSteinbuschHWM, et al.The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res1983; 277: 355–360.
SatoTSugayaTTalukderAH, et al.Dual action of serotonin on local excitatory and inhibitory neural circuits regulating the corticotropin-releasing factor neurons in the paraventricular nucleus of the hypothalamus. J Neuroendocrinol2023; 35: e13351.
92.
PompiliMSerafiniGInnamoratiM, et al.The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. Eur Arch Psychiatry Clin Neurosci2010; 260: 583–600.
93.
DaviuNFüzesiTRoseneggerDG, et al.Paraventricular nucleus CRH neurons encode stress controllability and regulate defensive behavior selection. Nat Neurosci2020; 23: 398–410.
94.
AguileraGLiuY. The molecular physiology of CRH neurons. Front Neuroendocrinol2012; 33: 67.
95.
OnoDMukaiYHungCJ, et al.The mammalian circadian pacemaker regulates wakefulness via CRF neurons in the paraventricular nucleus of the hypothalamus. Sci Adv2020; 6: eabd0384.
96.
Van EgrooMKoshmanovaEVandewalleG, et al.Importance of the locus coeruleus-norepinephrine system in sleep-wake regulation: implications for aging and Alzheimer’s disease. Sleep Med Rev2022; 62: 101592.
97.
Peter-DerexLYamminePBastujiH, et al.Sleep and Alzheimer’s disease. Sleep Med Rev2015; 19: 29–38.
98.
MontplaisirJPetitDGauthierS, et al.Sleep disturbances and EEG slowing in Alzheimer’s disease. Sleep Res Online1998; 1: 147–151.
99.
JuY-ESMcLelandJSToedebuschCD, et al.Sleep quality and preclinical Alzheimer disease. JAMA Neurol2013; 70: 587–593.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
